Chimeric Antigen Receptor T Cells, the Shock of the New
- PMID: 34914647
- DOI: 10.1097/CCM.0000000000005153
Chimeric Antigen Receptor T Cells, the Shock of the New
Comment on
-
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.Crit Care Med. 2022 Jan 1;50(1):81-92. doi: 10.1097/CCM.0000000000005149. Crit Care Med. 2022. PMID: 34259446 Free PMC article.
References
-
- Hulvat MC. Cancer incidence and trends. Surg Clin North Am. 2020; 100:469–481
-
- Darmon M, Bourmaud A, Georges Q, et al. Changes in critically ill cancer patients’ short-term outcome over the last decades: Results of systematic review with meta-analysis on individual data. Intensive Care Med. 2019; 45:977–987
-
- Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019; 94:S3–S9
-
- Gutierrez C, Brown ART, May HP, et al. Critically Ill Patients Treated for Chimeric Antigen Receptor–Related Toxicity: A Multicenter Study. Crit Care Med. 2022; 50:81–92
-
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019; 34:45–55
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources